Drugs / Vortioxetine
Vortioxetine
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed major depressive disorder 1 milestone | |||||
| Filed | Japan (PMDA) | — | major depressive disorder | 2018-09-28 | “today announced the submission of a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for vortioxetine” takeda.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (6) | US (FDA) | TRINTELLIX | — | 2017-03-10 – 2023-08-23 | fda.gov ↗ |
| Approved | EU (EMA) | Brintellix | — | 2013-12-18 | europa.eu ↗ |
| Approved | US (FDA) | TRINTELLIX | — | 2013-09-30 | fda.gov ↗ |
Trials 94 · started per year
today
US approved 2013
EU approved 2013
1
2
11
1
6
6
6
8
6
13
3
2
7
6
2
5
2
1
4
2
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04456777 | Jul 2020 → Jul 2022 | cognitive disorder | Alen Greš | Unknown | No outcome recorded |
| Phase 0 | NCT02454426 | Apr → Jun 2016 | coronary artery disorder, major depressive disorder | Thomas Jefferson University | Withdrawn | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT05416762 | Sep → Nov 2022 | major depressive disorder | Seasons Biotechnology (Taizhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05416957 | Sep → Oct 2022 | major depressive disorder | Seasons Biotechnology (Taizhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03884491 | Mar → Jun 2019 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02386488 | Mar → May 2015 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02170220 | Jul → Nov 2014 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02112903 | Apr → Sep 2014 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02072278 | Feb → Nov 2014 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT01676571 | Oct → Nov 2012 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT01607125 | Jul 2012 → Sep 2013 | depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT01299805 | Mar → Jun 2011 | — | Takeda | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05814640 | Feb 2023 → Dec 2026 expected | major depressive disorder, splenic sequestration | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 213 trials · 2 met primary · 3 missed | ||||||
| Phase 2 | NCT07284628 | Jun 2026 → Jun 2029 expected | glioblastoma | University of Zurich | Recruiting | No outcome recorded |
| Phase 2 | NCT07000734 | Jul 2025 → Apr 2026 | cardiovascular disorder, cognitive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT06604520 | Mar 2025 → May 2029 expected | behavioral variant of frontotemporal dementia | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT05047952 | Sep 2021 → Feb 2023 | cognitive disorder, post-COVID-19 disorder | Brain and Cognition Discovery Foundation | Completed | No outcome recorded |
| Phase 2 | NCT03766867 | Dec 2018 → Jul 2019 | major depressive disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 2 | NCT03598868 | Aug 2018 → Sep 2021 | bipolar depression | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02919501 | Sep 2016 → Apr 2017 | major depressive disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 2 | NCT02528409 | Jun 2016 → Nov 2018 | binge eating disorder | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT02327013 | Dec 2014 → Sep 2016 | attention deficit-hyperactivity disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 2 | NCT01491035 | Apr 2012 → Dec 2014 | anxiety disorder, depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT01564862 | Apr 2012 → Feb 2014 | major depressive disorder | Takeda | Completed | Met primary |
| Phase 2 | NCT00761306 | Jun 2007 → Sep 2008 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT00839423 | Aug 2006 → Aug 2007 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT04895488 | Jan 2022 → Dec 2024 | cognitive impairment with or without cerebellar ataxia | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 2/3 | NCT03053362 | May 2017 → Aug 2018 | major depressive disorder | Brain and Cognition Discovery Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT01255787 | Nov 2010 → Mar 2012 | major depressive disorder | Takeda | Completed | Missed primary |
| Phase 341 trials · 12 met primary · 10 missed | ||||||
| Phase 3 | NCT07204314 | Oct 2025 → Sep 2029 expected | major depressive disorder | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06561438 | Aug 2024 → Jun 2025 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 3 | NCT06025474 | Jan → Oct 2023 | burning mouth syndrome | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT05104918 | Feb → Apr 2022 | major depressive disorder | Scotmann Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT05014919 | Aug 2021 → Mar 2022 | depressive disorder | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT04818099 | Oct 2020 → Oct 2023 | radiation-induced disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04035850 | Aug 2019 → Aug 2021 | — | Noam Soreni | Withdrawn | No outcome recorded |
| Phase 3 | NCT03108625 | Mar 2017 → Apr 2020 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02845349 | Oct 2016 → Oct 2018 | major depressive disorder, traumatic brain injury | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02871297 | Aug 2016 → Mar 2022 | major depressive disorder | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT02709655 | May 2016 → Jan 2022 | major depressive disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 3 | NCT02709746 | May 2016 → Jul 2019 | major depressive disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 3 | NCT02389816 | Apr 2015 → Mar 2018 | major depressive disorder | Takeda | Completed | Met primary |
| Phase 3 | NCT02272517 | Dec 2014 → Mar 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02279966 | Oct 2014 → Feb 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02279953 | Oct 2014 → Apr 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01571453 | May 2012 → Oct 2013 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT01488071 | Jan → Dec 2012 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT01422213 | Dec 2011 → May 2013 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT01395147 | Jul 2011 → May 2013 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01364649 | Jun 2011 → Dec 2013 | — | Takeda | Completed | Met primary |
| Phase 3 | NCT01355081 | May 2011 → Dec 2012 | major depressive disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT01323478 | Apr 2011 → Sep 2012 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01152996 | Sep 2010 → May 2013 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01179516 | Aug 2010 → May 2012 | major depressive disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT01163266 | Jul 2010 → Jan 2012 | major depressive disorder | Takeda | Completed | Met primary |
| Phase 3 | NCT01153009 | Jun 2010 → Mar 2012 | major depressive disorder | Takeda | Completed | Mixed |
| Phase 3 | NCT01140906 | May 2010 → Sep 2011 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT00811252 | Jan 2009 → Feb 2010 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT00788034 | Oct 2008 → Jun 2010 | generalized anxiety disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 3 | NCT00744627 | Sep 2008 → Jul 2009 | generalized anxiety disorder | Takeda | Completed | Met primary |
| Phase 3 | NCT00735709 | Aug 2008 → Jul 2009 | major depressive disorder | Takeda | Completed | Met primary |
| Phase 3 | NCT00707980 | Jun 2008 → Jul 2010 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00730691 | Jun 2008 → Feb 2009 | generalized anxiety disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT00731120 | Jun 2008 → Jan 2009 | generalized anxiety disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT00734071 | Jun 2008 → Jan 2009 | generalized anxiety disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT00694304 | May 2008 → Mar 2010 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00672958 | Apr → Nov 2008 | major depressive disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT00672620 | Apr → Nov 2008 | major depressive disorder | Takeda | Completed | Missed primary |
| Phase 3 | NCT00635219 | Feb 2008 → Apr 2009 | major depressive disorder | H. Lundbeck A/S | Completed | Missed primary |
| Phase 3 | NCT00596817 | Dec 2007 → Sep 2009 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 424 trials · 3 met primary · 1 missed | ||||||
| Phase 4 | NCT07266545 | Feb 2026 → Dec 2028 expected | bipolar depression, major depressive disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06805266 | Feb 2025 → Dec 2026 expected | Parkinson disease, depressive disorder | Marianna Amboni | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05481957 | Mar 2022 → Jun 2023 | bipolar depression | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT03830827 | Sep 2020 → Apr 2021 | cognitive impairment with or without cerebellar ataxia, depressive disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04448431 | Jun 2020 → Jan 2022 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 4 | NCT04294654 | Feb 2020 → Jul 2022 | dementia, major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT04288895 | Feb 2020 → Feb 2022 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT04220996 | Dec 2019 → Mar 2021 | anxiety disorder, major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT04301492 | Nov 2019 → Jul 2023 | depressive disorder | IRCCS San Raffaele Roma | Unknown | No outcome recorded |
| Phase 4 | NCT03580967 | Jul 2019 → Jul 2021 | major depressive disorder, type 2 diabetes mellitus | Todd Doyle | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03835715 | Feb 2019 → Feb 2020 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT03779789 | Feb 2019 → Feb 2023 | major depressive disorder | Azienda Ospedaliera Universitaria Integrata Verona | Completed | Missed primary |
| Phase 4 | NCT02969876 | Aug 2017 → Aug 2018 | major depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02972632 | Dec 2016 → Feb 2018 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02749721 | Dec 2016 → Jan 2019 | major depressive disorder | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02932904 | Nov 2016 → May 2017 | — | Takeda | Completed | Mixed |
| Phase 4 | NCT03272711 | Aug 2016 → Jan 2019 | subjective cognitive decline | Washington University School of Medicine | Completed | Met primary |
| Phase 4 | NCT02637466 | Jul 2016 → Jul 2018 | female breast carcinoma, major depressive disorder | University of Miami | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03978286 | Jun 2016 → Jun 2017 | depressive disorder, type 2 diabetes mellitus | Universidad Juárez Autónoma de Tabasco | Completed | No outcome recorded |
| Phase 4 | NCT02234362 | Jun 2015 → Sep 2016 | major depressive disorder, vascular disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02395510 | May 2015 → Jun 2016 | panic disorder | Siyan Clinical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02371980 | Feb 2015 → Mar 2019 | major depressive disorder | Takeda | Completed | Met primary |
| Phase 4 | NCT02332954 | Feb 2015 → Jul 2017 | major depressive disorder | Lundbeck Canada Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02294305 | Dec 2014 → Nov 2016 | major depressive disorder, social phobia | The Medical Research Network | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT04498897 Comparator | Jan 2019 → Apr 2021 | alcohol dependence, major depressive disorder | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2/3 | NCT03485274 Comparator | Jul 2018 → Feb 2023 | anxiety, cannabis dependence, depressive disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT03855865 Comparator | Jul 2019 → Dec 2020 | major depressive disorder | Naurex, Inc | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02637895 Comparator | Dec 2016 → Jan 2020 | post-traumatic stress disorder | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT03187093 Comparator | Oct 2016 → Apr 2019 | major depressive disorder | Oleg Levada | Unknown | No outcome recorded |
| Phase 4 | NCT02357797 Comparator | Feb 2016 → Oct 2023 | schizophrenia | Northwell Health | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2022-01-01 | Alembic Pharmaceuticals Ltd. | Regulatory 7th January, 2022, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg. |
| 2021-09-18 | Zydus Lifesciences Limited | Regulatory Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets zyduslife.com ↗
Zydus Cadila has received final approval from the USFDA to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets). |
| 2019-09-20 | Takeda | Regulatory Takeda and Lundbeck announce Ministry of Health, Labour and Welfare (MHLW) approval of Trintellix ® in Japan takeda.com ↗
Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE: TAK ) (“Takeda”) and H. Lundbeck A/S (“Lundbeck”) jointly announced today that the MHLW of Japan approved Trintellix ® (vortioxetine) for the treatment of depression and depressed state. |
| 2018-09-28 | Takeda | Regulatory Takeda and Lundbeck Submit New Drug Application (NDA) for Vortioxetine in Japan for the Treatment of Major Depressive Disorder (MDD) takeda.com ↗ |
| 2018-06-08 | Takeda | Results Positive clinical phase III results of vortioxetine in Japanese patients takeda.com ↗
Takeda Pharmaceutical Company Limited [TSE: 4502] (“Takeda”) and its partner, H. Lundbeck A/S (“Lundbeck”) today announced positive results from the pivotal study (NCT02389816) with vortioxetine in adults with Major Depressive Disorder (MDD) conducted in Japan. |
| 2018-05-02 | Takeda | Regulatory TRINTELLIX ® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD) takeda.com ↗
Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX ® (vortioxetine). |
| 2018-05-02 | H. Lundbeck A/S | Regulatory Trintellix Prescribing Information Updated to Include New Data Showing Improvement in Processing Speed lundbeck.com ↗
Osaka, Japan and Deerfield, Ill. (May 2, 2018) – Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). |
| 2017-06-23 | Takeda | Regulatory Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix® (vortioxetine) sNDA takeda.com ↗
The CRL does not change the FDA-approved current prescribing information for Trintellix. |
| 2016-03-29 | Takeda | Regulatory Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA takeda.com ↗
The CRL does not apply to the use of Brintellix in MDD. |
| 2016-02-04 | Takeda | Regulatory FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD) takeda.com ↗
The panel voted 8-2 that substantial evidence has been presented to support a claim of effectiveness for Brintellix for treating certain aspects of cognitive dysfunction in MDD |
| 2015-08-11 | Takeda | Regulatory FDA Accepts a Supplemental New Drug Application for Review of Brintellix ® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder takeda.com ↗
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. |
| 2014-06-18 | Takeda | Results Results of a New Study of Brintellix ® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction takeda.com ↗
Takeda and Lundbeck Announce Results at American Society of Clinical Psychopharmacology Annual Meeting Hollywood, Fla. U.S.A., June 17, 2014 and Osaka, Japan, June 18, 2014 —Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced that the companies presented results about sexual functioning from a head-to-head study of Brintellix ® (vortioxetine) vs. escitalopram in patients with well treated major depressive disorder (MDD) experiencing treatment-emergent sexual dysfunction (TESD). |
| 2014-06-17 | Takeda | Results New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix ® (vortioxetine) for Major Depressive Disorder takeda.com ↗ |
All press releases naming this drug 16 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 103 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vortioxetine | “Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of...” NCT03321526 ↗97“Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes” NCT00596817 ↗ |
| Known as | Brintellix | “Vortioxetine (Brintellix®), a novel antidepressant for the treatment of adult with major depressive disorder, has been approved by the Chinese Food and Drug Administration in...” NCT03830827 ↗2“Vortioxetine is approved by the U.S. Food and Drug Administration as a treatment for depression, and also goes by the name Trintellix (formerly known as Brintellix).” NCT03272711 ↗ “to receive study drug (Brintellix drops 20 mg/ml).” NCT04301492 ↗ |
| Known as | Lu AA21004 | “Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu...” NCT02072278 ↗15“A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication” NCT01488071 ↗ “Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study” PMID 24257717 ↗ May 2014 “Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder” NCT01491035 ↗ “Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes” NCT00596817 ↗ “Drug: Vortioxetine (Lu AA21004)” NCT01422213 ↗ “Vortioxetine (Lu AA21004)” NCT00694304 ↗ “Vortioxetine (Lu AA21004)” NCT00635219 ↗ “Vortioxetine (Lu AA21004)” NCT01607125 ↗ “vortioxetine (Lu AA21004)” NCT01564862 ↗ “Vortioxetine (Lu AA21004)” NCT00761306 ↗ |
| Known as | Trintellix | “This study will look at an anti-depressant medication called vortioxetine (Trintellix).” NCT03580967 ↗ |
| Known as | Vortioxetine Hemihydrobromide | “Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg” NCT05416762 ↗ |
| Action | Inhibit | “inhibitor of the 5-HT transporter” PMID 23252878 ↗ Jan 2013 |
| Route | Oral | “encapsulated tablets, daily, orally” NCT00596817 ↗ |